Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Gynecologic 1

Conditions

Colorectal Neoplasms 2Prostatic Neoplasms 1Prostate Cancer Metastatic 1Colorectal and Ovarian Cancer Patients With Liver Metastases 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Abituzumab × Clear all
NCT03688230 2020-03-18

AMELION

SFJ Pharmaceuticals, Inc.

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT00958477 2017-08-02

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
26 enrolled 44 charts
Genitourinary

Prostatic Neoplasms

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
232 enrolled 20 charts
Gastrointestinal

Colorectal Neoplasms

NCT00848510 2015-12-14

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
41 enrolled 18 charts
GastrointestinalGynecologic

Colorectal and Ovarian Cancer Patients With Liver Metastases

NCT01360840 2015-12-14

PERSEUS

EMD Serono

Phase 2 Completed
180 enrolled 23 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡